Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.70) by 7.14 percent. This is a 74.14 percent increase over losses of $(2.90) per share from the same period last year. The company reported quarterly sales of $1.882 million which beat the analyst consensus estimate of $500.000 thousand by 276.40 percent. This is a 44.33 percent increase over sales of $1.304 million the same period last year.